ArticleEvidence-based complementary and alternative medicine : eCAM2018
Cytotoxic Effect of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) on Liver Cancer Cell Integrated with Hepatitis B Genome, Hep3B.
Article in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Thymoquinone inhibits proliferation and impairs wound closure dynamics via apoptosis and autophagy-related pathways in multiple cancer cell lines.Molecular biology reports · 2026Article
- Bile acids and nanotechnology as emerging platforms for drug delivery.Therapeutic delivery · 2026Review
- Potential role of thymoquinone to treat gastrointestinal cancers: insights into its molecular mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Clinical andInfectious disorders drug targets · 2025Review
- Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023Review
- Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer.Drug delivery · 2022Review
- Development of Stable Liposomal Drug Delivery System of Thymoquinone and Its In Vitro Anticancer Studies Using Breast Cancer and Cervical Cancer Cell Lines.Molecules (Basel, Switzerland) · 2022Article
- Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging.Bioactive materials · 2022Review
- Thymoquinone, as a Novel Therapeutic Candidate of Cancers.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Therapeutic perspective of thymoquinone: A mechanistic treatise.Food science & nutrition · 2021Review
- Immune cell engineering: opportunities in lung cancer therapeutics.Drug delivery and translational research · 2020Review
- Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2019Review
- Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) onEvidence-based complementary and alternative medicine : eCAM · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymoquinone (TQ), a bioactive compound found in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.